Showing results (81-90 of 191) with videos related to
Sort By:
Pageof 20
Behavioural Brain Research|July 5, 2003
The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibitionP D Shilling, E Richelson, D FeifelMayo Clinic Proceedings|December 1, 1983
Thrombin binding to human brain and spinal cordM McKinney, R M Snider, E RichelsonEuropean Journal of Pharmacology|March 5, 1997
Muscarinic m4 receptor activation by some atypical antipsychotic drugsX P Zeng, F Le, E RichelsonMayo Clinic Proceedings|June 1, 1979
Series on pharmacology in practice. 1. Drugs that alter mood. II. LithiumA H Rosenbaum, T Maruta, E RichelsonMayo Clinic Proceedings|May 1, 1979
Series on pharmacology in practice: 1. Drugs that alter mood. I. Tricyclic agents and monoamine oxidase inhibitorsA H Rosenbaum, T Maruta, E RichelsonBiochemical Pharmacology|July 15, 1988
Desensitization of neurotensin receptor-mediated cyclic GMP formation in neuroblastoma clone N1E-115J A Gilbert, T R Strobel, E RichelsonBiochemical Pharmacology|October 15, 1985
Inhibition by ethanol of forskolin-stimulated adenylate cyclase in a murine neuroblastoma clone (N1E-115)S Stenstrom, M Seppala, M Pfenning, et al.Gastroenterology|December 1, 1982
Perturbation of gastric emptying and duodenal motility through the central nervous systemD G Thompson, E Richelson, J R MalageladaRegulatory Peptides|October 18, 2000
Neurotensin: peptide for the next millenniumB M Tyler-McMahon, M Boules, E RichelsonMayo Clinic Proceedings|November 1, 1985
Antipsychotic agents: a clinical updateJ L Black, E Richelson, J W RichardsonPageof 20